STOCK TITAN

Bristol-Myers Squibb Co Stock Price, News & Analysis

BMY NYSE

Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.

Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical leader developing innovative therapies in oncology, cardiovascular diseases, and immunology. This dedicated news hub provides investors and healthcare professionals with direct access to BMY's latest developments, including FDA approvals, clinical trial results, and strategic partnerships.

Track critical updates through curated press releases covering drug development milestones, financial earnings reports, and research collaborations. Our aggregation ensures you never miss regulatory filings, product launch announcements, or patent developments impacting BMY's market position.

Discover timely information on therapeutic advancements in immuno-oncology and hematology, plus insights into global healthcare trends affecting pharmaceutical operations. Bookmark this page for streamlined monitoring of BMY's scientific innovations and corporate announcements essential for informed analysis.

Rhea-AI Summary

Bristol Myers Squibb (BMY) reported strong Q3 2024 results with revenues of $11.9 billion, up 8% year-over-year. The Growth Portfolio revenues reached $5.8 billion, increasing 18%. GAAP EPS was $0.60 and Non-GAAP EPS was $1.80, including a net impact of $(0.09) due to Acquired IPRD charges. U.S. revenues increased 9% to $8.2 billion, while International revenues grew 7% to $3.7 billion. The company achieved U.S. approval for Cobenfy for schizophrenia treatment and raised its 2024 revenue guidance to approximately +5% (+6% excluding foreign exchange), with updated Non-GAAP EPS range of $0.75 to $0.95.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
-
Rhea-AI Summary

Bristol Myers Squibb (BMY) will present new clinical and health economics data for COBENFY™ (xanomeline and trospium chloride) at Psych Congress 2024 in Boston, October 29 - November 2. The presentations will showcase results from the 52-week EMERGENT-4 and EMERGENT-5 trials, focusing on safety, efficacy, and patient satisfaction in treating adult schizophrenia.

Key presentations include long-term safety data, patient satisfaction studies, quality of life changes, and comparative efficacy analyses versus other antipsychotics. The research demonstrates COBENFY as a differentiated treatment option, following its recent FDA approval. Presentations will take place in the Exhibit Hall on October 31 and November 1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
conferences
-
Rhea-AI Summary

Bristol Myers Squibb announced FDA approval of Opdivo® (nivolumab) for the perioperative treatment of adult patients with resectable non-small cell lung cancer (NSCLC). The approval is based on the CheckMate-77T trial, where Opdivo with chemotherapy showed significantly longer event-free survival compared to chemotherapy alone. Key findings include:

- 42% reduction in risk of disease recurrence, progression, or death
- 70% 18-month event-free survival rate vs 50% in control arm
- 25% pathologic complete response rate vs 4.7% in control arm

Opdivo is now the only PD-1 inhibitor approved for resectable NSCLC in both neoadjuvant-only and perioperative regimens. This expands Bristol Myers Squibb's thoracic portfolio and reinforces their commitment to early-stage disease treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
Rhea-AI Summary

Bristol Myers Squibb (NYSE:BMY) announced positive results from two trials demonstrating Sotyktu (deucravacitinib) efficacy in moderate-to-severe scalp psoriasis and real-world settings. The Phase 3b/4 PSORIATYK SCALP trial showed Sotyktu's superiority over placebo across all primary and secondary endpoints at Week 16. Notably, 48.5% of Sotyktu-treated patients achieved clear/almost clear scalp psoriasis compared to 13.7% on placebo.

The real-world RePhlect registry analysis revealed that six months of Sotyktu treatment was consistent with efficacy outcomes observed in previous clinical studies. Patients achieved significant decreases in disease severity measures, with 67.9% reaching PASI scores ≤3 and 64.1% achieving BSA ≤3%.

Sotyktu's safety profile in PSORIATYK SCALP was consistent with previous trials. These results reinforce Sotyktu as a potential oral standard of care for moderate-to-severe psoriasis, especially with scalp involvement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
-
Rhea-AI Summary

PureTech Health announced that KarXT, now marketed as Cobenfy, has received FDA approval for treating schizophrenia in adults. This milestone triggers $29 million in payments to PureTech and unlocks potential future payments and royalties. Cobenfy, invented by PureTech, is the first new drug mechanism approved in over 50 years for schizophrenia treatment.

The approval validates PureTech's unique R&D model, which has now produced three FDA-approved therapeutics. PureTech has generated approximately $1.1 billion from its involvement with Karuna Therapeutics, which was recently acquired by Bristol Myers Squibb. This success enables PureTech to self-fund the advancement of several programs, including LYT-100 for idiopathic pulmonary fibrosis, with topline data expected by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) has received FDA approval for COBENFY™ (xanomeline and trospium chloride), a first-in-class oral medication for treating schizophrenia in adults. This groundbreaking approval marks the first new pharmacological approach to schizophrenia treatment in decades, targeting M1 and M4 receptors without blocking D2 receptors.

The approval is based on the EMERGENT clinical program, which demonstrated significant reductions in schizophrenia symptoms compared to placebo. In Phase 3 trials, COBENFY showed 9.6-point and 8.4-point reductions in PANSS total scores compared to placebo at week five.

COBENFY's safety profile has been established in acute and long-term trials. Common adverse reactions include nausea, dyspepsia, and constipation. The drug does not carry atypical antipsychotic class warnings or a boxed warning.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) announced new data from the Phase 3 DAYBREAK trial for Zeposia (ozanimod) in treating relapsing forms of multiple sclerosis. The study demonstrated:

1. Sustained decreased rates of brain volume loss for up to 5 years of continuous treatment.
2. Low and stable rates of whole brain volume loss through Month 60.
3. Declining or stable incidence rates of treatment-emergent adverse events over 8+ years.
4. Consistent reductions in brain volume loss when switching from interferon beta-1a to Zeposia.

The data reinforces Zeposia's established safety and efficacy profile as an effective oral therapy for multiple sclerosis, particularly for newly diagnosed patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
none
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) released 10-year follow-up data from the CheckMate -067 Phase 3 trial showing continued long-term survival benefits of Opdivo® plus Yervoy® in advanced melanoma patients. At ten years, 43% of patients treated with the combination were still alive, compared to a 1-year survival rate of 25% a decade ago. Results showed a median overall survival (OS) of 71.9 months for the combination therapy, 36.9 months for Opdivo alone, and 19.9 months for Yervoy alone. These findings were presented at the ESMO Congress 2024 and published in The New England Journal of Medicine. The study included 945 patients, highlighting that durable clinical benefits were observed across subgroups, including those with BRAF mutant and wild-type tumors. Safety data showed no new adverse signals, and Grade 3/4 treatment-related adverse events were consistent with prior findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) has announced that it will release its third quarter 2024 financial results on Thursday, October 31, 2024. The company will host a conference call and live webcast at 8:00 a.m. ET on the same day to discuss the results and address questions from investors and analysts. Interested parties can listen to the webcast at http://investor.bms.com or register for the live call. A replay of the webcast and conference call will be available until November 14, 2024. This announcement provides investors and analysts with an opportunity to gain insights into BMY's financial performance and future outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
conferences earnings
News
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) has announced its latest dividend declarations. The Board of Directors has declared a quarterly dividend of $0.60 per share on the company's common stock, payable on November 1, 2024, to stockholders of record as of October 4, 2024. Additionally, a quarterly dividend of $0.50 per share has been declared on the company's convertible preferred stock, payable on December 2, 2024, to stockholders of record as of November 5, 2024. These dividend announcements demonstrate BMY's commitment to returning value to shareholders and maintaining its dividend program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
dividends

FAQ

What is the current stock price of Bristol-Myers Squibb Co (BMY)?

The current stock price of Bristol-Myers Squibb Co (BMY) is $46.34 as of September 16, 2025.

What is the market cap of Bristol-Myers Squibb Co (BMY)?

The market cap of Bristol-Myers Squibb Co (BMY) is approximately 94.3B.
Bristol-Myers Squibb Co

NYSE:BMY

BMY Rankings

BMY Stock Data

94.34B
2.03B
0.07%
82.82%
1.53%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
PRINCETON